Proposed Collection; 60-Day Comment Request Division of Cancer Epidemiology and Genetics Fellowship Program and Summer Student Applications (DCEG) (National Cancer Institute), 60407-60408 [2017-27415]
Download as PDF
<![CDATA[
Federal Register / Vol. 82, No. 243 / Wednesday, December 20, 2017 / Notices
sradovich on DSK3GMQ082PROD with NOTICES
immunotherapy using autologous (meaning
one individual is both the donor and the
recipient) T cells transfected with a retroviral
vector (including lentiviral vectors), wherein
the vector expresses a CAR having:
(1) a single antigen specificity; and
(2) comprising at least:
(a) the complementary determining region
(CDR) sequences of the anti-CD30 antibody
known as 5F11; and
(b) a T cell signaling domain;
for the prophylaxis and treatment of CD30expressing human cancers.’’
This technology discloses the
development of chimeric antigen
receptors that recognize the CD30
protein (also known as tumor necrosis
factor receptor superfamily member 8
(TNFRSF8)). CD30 is expressed on the
cell surface of several rare forms of
cancer, including Hodgkin lymphoma
(HL), Non-Hodgkin’s Lymphoma (NHL),
diffuse large B cell lymphoma (DLBCL),
peripheral T cell lymphoma not
otherwise specified (PTCL–NOS),
anaplastic large cell lymphoma (ALCL),
and angioimmunoblastic T cell
lymphoma (AITL). The development of
a new therapeutic targeting CD30 will
benefit public health by offering up a
treatment for these rare cancers in
instances when conventional first line
therapies are ineffective.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
be royalty bearing, and the prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published notice, the National
Cancer Institute receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public
may file comments or objections.
Comments and objections, other than
those in the form of a completed license
application, will not be treated
confidentially, and may be made
publicly available.
License applications submitted in
response to this Notice will be
presumed to contain business
confidential information and any release
of information in these license
applications will be made only as
required and upon a request under the
Freedom of Information Act, 5 U.S.C.
552.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institutes of Health
National Institute of Neurological
Disorders and Stroke Notice of Closed
Meetings
Proposed Collection; 60-Day Comment
Request Division of Cancer
Epidemiology and Genetics Fellowship
Program and Summer Student
Applications (DCEG) (National Cancer
Institute)
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Neurological Disorders and Stroke
Technologies for Large-Scale Recording and
Modulation in the Nervous System.
Date: January 18–19, 2018.
Time: 8:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Alexandria Old Town, 1767
King Street, Alexandria, VA 22314.
Contact Person: Ernest Lyons, Ph.D.,
Scientific Review Officer; Scientific Review
Branch; NINDS/NIH/DHHS; Neuroscience
Center; 6001 Executive Blvd., Suite 3204,
MSC 9529, Bethesda, MD 20892–9529; 301–
496–4056; lyonse@ninds.nih.gov.
Name of Committee: Neurological Sciences
Training Initial Review Group; NST–1
Subcommittee.
Date: January 29–30, 2018.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Alexandria Old Town, 1767
King Street, Alexandria, VA 22314.
Contact Person: William Benzing, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, NINDS/NIH/DHHS, Neuroscience
Center, 6001 Executive Blvd., Suite 3204,
MSC 9529, Bethesda, MD 20892–9529, 301–
496–0660, benzingw@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences, National Institutes of Health,
HHS)
Dated: December 8, 2017.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
Dated: December 14, 2017.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–27416 Filed 12–19–17; 8:45 am]
[FR Doc. 2017–27329 Filed 12–19–17; 8:45 am]
BILLING CODE 4140–01–P
BILLING CODE 4140–01–P
VerDate Sep<11>2014
21:36 Dec 19, 2017
Jkt 244001
60407
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
National Institutes of Health.
Notice.
AGENCY:
ACTION:
In compliance with the
requirement of the Paperwork
Reduction Act of 1995 to provide
opportunity for public comment on
proposed data collection projects, the
National Cancer Institute (NCI) will
publish periodic summaries of propose
projects to be submitted to the Office of
Management and Budget (OMB) for
review and approval.
DATES: Comments regarding this
information collection are best assured
of having their full effect if received
within 60 days of the date of this
publication.
FOR FURTHER INFORMATION CONTACT: To
obtain a copy of the data collection
plans and instruments, submit
comments in writing, or request more
information on the proposed project,
contact: Jackie Lavigne, Ph.D., M.P.H.,
Chief, Office of Education, Division of
Cancer Epidemiology and Genetics,
9609 Medical Center Drive, MSC,
Bethesda, Maryland 20892 or call nontoll-free number 240.276.7237or Email
your request, including your address to:
lavignej@mail.nih.gov. Formal requests
for additional plans and instruments
must be requested in writing.
SUPPLEMENTARY INFORMATION: Section
3506(c)(2)(A) of the Paperwork
Reduction Act of 1995 requires: Written
comments and/or suggestions from the
public and affected agencies are invited
to address one or more of the following
points: (1) Whether the proposed
collection of information is necessary
for the proper performance of the
function of the agency, including
whether the information will have
practical utility; (2) The accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used; (3)
Ways to enhance the quality, utility, and
clarity of the information to be
collected; and (4) Ways to minimize’s
the burden of the collection of
information on those who are to
respond, including the use of
appropriate automated, electronic,
mechanical, or other technological
SUMMARY:
E:\FR\FM\20DEN1.SGM
20DEN1
60408
Federal Register / Vol. 82, No. 243 / Wednesday, December 20, 2017 / Notices
collection techniques or other forms of
information technology.
Proposed Collection Title: Fellowship
Program and Summer Student
Applications 0925–0716, Exp., date 5/
31/2018, Extension, National Cancer
Institute (NCI), National Institutes of
Health (NIH).
Need and Use of Information
Collection: This is a request for approval
of an ‘‘Extension’’ for three years. The
National Cancer Institute, Division of
Cancer Epidemiology and Genetics
(DCEG) Office of Education administers
a variety of programs and initiatives to
recruit pre-college through post-doctoral
educational level individuals into the
Intramural Research Program to
facilitate their development into future
biomedical scientists. DCEG trains post-
doctoral, doctoral candidates, graduate
and baccalaureate students, through full
time fellowships, summer fellowships,
and internships in preparation for
research careers in cancer epidemiology
and genetics. The proposed information
collection involves brief online
applications completed by applicants to
the full time and the summer fellowship
programs. Full-time fellowships
include: Full-time Equivalents (FTE)
and non-FTE fellowships for US
citizens, permanent residents and
international fellows. These
applications are essential to the
administration of these training
programs as they enable OE to
determine the eligibility and quality of
potential awardees; to assess their
potential as future scientists; to
determine where mutual research
interests exist; and to make decisions
regarding which applicants will be
proposed and approved for traineeship
awards. In each case, completing the
application is voluntary, but in order to
receive due consideration, the
prospective trainee is encouraged to
complete all relevant fields. The
information is for internal use to make
decisions about prospective fellows and
students that could benefit from the
DCEG program.
OMB approval is requested for 3
years. There are no costs to respondents
other than their time. The total
estimated annualized burden hours are
218 hours.
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Type of respondent
Number of
responses per
respondent
Average
time per
response
(in hours)
Total
annual
burden
hour
Full-time Fellows ..............................................................................................
Summer Students ............................................................................................
150
430
1
1
30/60
20/60
75
143
Total ..........................................................................................................
580
580
........................
218
Dated: December 4, 2017.
Karla Bailey,
Project Clearance Liaison, National Cancer
Institute, National Institutes of Health.
indicated licensing contact at the
Technology Transfer and Intellectual
Property Office, National Institute of
Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852; tel.
301–496–2644. A signed Confidential
Disclosure Agreement will be required
to receive copies of unpublished patent
applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
[FR Doc. 2017–27415 Filed 12–19–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT: Dr.
Natalie Greco, 301–761–7898;
Natalie.Greco@nih.gov. Licensing
information and copies of the patent
applications listed below may be
obtained by communicating with the
sradovich on DSK3GMQ082PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
21:36 Dec 19, 2017
Jkt 244001
Enhanced Tissue Clearing Solution,
Clearing-Enhanced 3D (Ce3D),
Compatible With Advanced
Fluorescence Microscopy Imaging
Description of Technology: NIH
immunologists have created a solution,
Clearing-enhanced 3D (Ce3D), that can
be used to make entire organs extremely
transparent. This allows the tissue to be
imaged using advanced fluorescence
microscopy techniques. Unlike current
tissue clearing solutions, the Ce3D
tissue clearing solution is robustly
compatible with a variety of staining
methods, and preserves tissue
morphology and reporter fluorescence.
Ce3D enabled microscopy provides
unprecedented insight into the spatial
organization of cells within intact
organs. Further, when Ce3D enabled
microscopy is coupled with multiplexed
staining and a newly developed analysis
pipeline, investigators are able to
extensively characterize densely packed
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
cells in situ, providing advantages to
phenotyping cells with flow cytometric
techniques.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404, as well as for further
development and evaluation under a
research collaboration.
Potential Commercial Applications:
• Research reagent—can be applied to
a variety of biological disciplines.
• Diagnostic medical imaging
reagent—characterization of disease
state/condition.
Competitive Advantages:
• Simple, quick and inexpensive
procedure that has been extensively
validated.
• Generates excellent tissue
transparency, resulting in high quality
images.
• Compatible with highly
multiplexed staining/labeling
techniques, including antibody-based
methods, fluorescently tagged reporter
proteins, and RNA–FISH.
• Fluorescence is maintained in
diverse fluorescent proteins and
fluorophores.
• Enables quantitative analysis of
tissue composition and cellular
distribution in whole organs, and has
advantages over flow cytometric
techniques.
Development Stage:
E:\FR\FM\20DEN1.SGM
20DEN1
]]>Agencies
[Federal Register Volume 82, Number 243 (Wednesday, December 20, 2017)]
[Notices]
[Pages 60407-60408]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-27415]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Proposed Collection; 60-Day Comment Request Division of Cancer
Epidemiology and Genetics Fellowship Program and Summer Student
Applications (DCEG) (National Cancer Institute)
AGENCY: National Institutes of Health.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: In compliance with the requirement of the Paperwork Reduction
Act of 1995 to provide opportunity for public comment on proposed data
collection projects, the National Cancer Institute (NCI) will publish
periodic summaries of propose projects to be submitted to the Office of
Management and Budget (OMB) for review and approval.
DATES: Comments regarding this information collection are best assured
of having their full effect if received within 60 days of the date of
this publication.
FOR FURTHER INFORMATION CONTACT: To obtain a copy of the data
collection plans and instruments, submit comments in writing, or
request more information on the proposed project, contact: Jackie
Lavigne, Ph.D., M.P.H., Chief, Office of Education, Division of Cancer
Epidemiology and Genetics, 9609 Medical Center Drive, MSC, Bethesda,
Maryland 20892 or call non-toll-free number 240.276.7237or Email your
request, including your address to: [email protected]. Formal
requests for additional plans and instruments must be requested in
writing.
SUPPLEMENTARY INFORMATION: Section 3506(c)(2)(A) of the Paperwork
Reduction Act of 1995 requires: Written comments and/or suggestions
from the public and affected agencies are invited to address one or
more of the following points: (1) Whether the proposed collection of
information is necessary for the proper performance of the function of
the agency, including whether the information will have practical
utility; (2) The accuracy of the agency's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) Ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) Ways
to minimize's the burden of the collection of information on those who
are to respond, including the use of appropriate automated, electronic,
mechanical, or other technological
[[Page 60408]]
collection techniques or other forms of information technology.
Proposed Collection Title: Fellowship Program and Summer Student
Applications 0925-0716, Exp., date 5/31/2018, Extension, National
Cancer Institute (NCI), National Institutes of Health (NIH).
Need and Use of Information Collection: This is a request for
approval of an ``Extension'' for three years. The National Cancer
Institute, Division of Cancer Epidemiology and Genetics (DCEG) Office
of Education administers a variety of programs and initiatives to
recruit pre-college through post-doctoral educational level individuals
into the Intramural Research Program to facilitate their development
into future biomedical scientists. DCEG trains post-doctoral, doctoral
candidates, graduate and baccalaureate students, through full time
fellowships, summer fellowships, and internships in preparation for
research careers in cancer epidemiology and genetics. The proposed
information collection involves brief online applications completed by
applicants to the full time and the summer fellowship programs. Full-
time fellowships include: Full-time Equivalents (FTE) and non-FTE
fellowships for US citizens, permanent residents and international
fellows. These applications are essential to the administration of
these training programs as they enable OE to determine the eligibility
and quality of potential awardees; to assess their potential as future
scientists; to determine where mutual research interests exist; and to
make decisions regarding which applicants will be proposed and approved
for traineeship awards. In each case, completing the application is
voluntary, but in order to receive due consideration, the prospective
trainee is encouraged to complete all relevant fields. The information
is for internal use to make decisions about prospective fellows and
students that could benefit from the DCEG program.
OMB approval is requested for 3 years. There are no costs to
respondents other than their time. The total estimated annualized
burden hours are 218 hours.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of Average time
Type of respondent Number of responses per per response Total annual
respondents respondent (in hours) burden hour
----------------------------------------------------------------------------------------------------------------
Full-time Fellows............................... 150 1 30/60 75
Summer Students................................. 430 1 20/60 143
---------------------------------------------------------------
Total....................................... 580 580 .............. 218
----------------------------------------------------------------------------------------------------------------
Dated: December 4, 2017.
Karla Bailey,
Project Clearance Liaison, National Cancer Institute, National
Institutes of Health.
[FR Doc. 2017-27415 Filed 12-19-17; 8:45 am]
BILLING CODE 4140-01-P
